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Fucoidan  attenuates  the  existing  allodynia  and  hyperalgesia  induced  by SNL.
Fucoidan  signiﬁcantly  inhibits  cytokines  production,  glial  and  ERK  activation.
The  analgesic  effect  of  fucoidan  may  be through  inhibiting  neuroimmune  activation.
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a  b  s  t  r  a  c  t
Fucoidan  is  an active  constituent  found  in  brown  seaweeds,  which  have  potential  neuroprotection.  The
current  study  aimed  to investigate  the  effects  of  fucoidan  on  the  maintenance  of  neuropathic  pain  induced
by L5  spinal  nerve  ligation  (SNL)  and  the  underlying  mechanism  related  to  the  spinal  neuroimmune
responses.  Animals  were  randomized  into  5 groups:  sham-operation  with  vehicle  and  SNL  with  vehicle
or fucoidan  (15,  50,  and  100  mg/kg).  Different  doses  of  fucoidan  or vehicle  were  administered  intrathecally
once  daily  from  postoperative  day  (POD)  11–20.  Mechanical  withdrawal  threshold  (MWT)  and  thermal
withdrawal  latency  (TWL)  was  measured  on  1 day  before  operation  and  days  10, 20, 22,  24, 26, 28,  30
after  operation.  Glial  activation  markers  such  as  glial ﬁbrillary  acidic  protein  (GFAP)  and  macrophage
antigen  complex-1  (mac-1),  inﬂammatory  cytokines  such  as  tumor  necrosis  factor  (TNF)-,  interleukin
(IL)-1  and  IL-6  activation,  and  extracellular  signalregulated  protein  kinase  (ERK)  activation  in the  lumbar
spinal cord  were  determined  on  day  30 after  operation.  The  results  showed  that  fucoidan  caused  dose-
dependently  attenuation  of  mechanical  allodynia  and  thermal  hyperalgesia.  Furthermore,  fucoidan  could
markedly  inhibit  neuroimmune  activation  characterized  by  glial  activation,  production  of  cytokines  as
well  as  ERK  activation.  The  analgesic  effect  of  intrathecal  fucoidan  in  rats  receiving  SNL  might  partly
attribute  to the  inhibition  of  neuroimmune  activation  associated  with  the maintenance  of  neuropathic
pain.
©  2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC. Introduction
Neuropathic pain develops as a consequence of a lesion or
isease affecting the somatosensory pathways in the peripheral
r central nervous system, and occurs in many neurological dis-
ases. Accumulating evidence indicates that central neuroimmune
ctivation and neuroinﬂammation play a pivotal role in the gen-
ration and maintenance of neuropathic pain [6,15]. After nerve
njury, spinal microglia and astrocytes are activated and release
ro-inﬂammatory cytokines, including interleukin (IL)-1, IL-6,
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304-3940/© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open
icenses/by-nc-nd/3.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
tumor necrosis factor-alpha (TNF-) and chemokines such as CC-
chemokine ligand (CCL) 2, CCL3, CCL5, CCL12 and fractalkine. These
cytokines and chemokines elicit chronic neuroinﬂammation and
enhance the central immune cascade, leading to neuropathic pain
[10,19]. Furthermore, activated glia cells interact with neurons
associated with pain transmission, and increase the excitability of
these neurons, resulting in neuropathic pain [10,14].
Neuropathic pain is characterized by spontaneous pain, hyper-
algesia and allodynias, affecting millions of people worldwide [24].
It is often severely debilitating and largely resistant to treatment.
Currently, available therapies shown to be effective in managing
neuropathic pain include opioids and tramadol, anticonvulsants,
antidepressants, topical treatments (lidocaine patch, capsaicin),
and ketamine. However, these treatments are either relatively
 access article under the CC BY-NC-ND license (http://creativecommons.org/
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neffective or accompanied by substantial side effects [16,20].
herefore, it is urgent to clarify the molecular mechanisms under-
ying neuropathic pain and establish novel therapeutic strategies.
Fucoidan is a sulfated polysaccharide which is one of the main
onstituents of brown seaweeds. Fucoidan exhibits a variety of
iological activities, including antioxidant, anti-apoptosis, antico-
gulant, antitumor, antiviral and anti-inﬂammatory activity [1,21].
owever, it was still unclear whether fucoidan had beneﬁcial
ffects in treating neuropathic pain. In the present study, we  tested
hether intrathecal fucoidan could attenuate nocifensive behavior
ssociated with neuropathic pain. We tried to explore the underly-
ng mechanism of the potential analgesic effect of fucoidan.
. Materials and methods
.1. Animals
Male SPF Sprague-Dawley rats (200–250 g) were used in the
resent study. All animals were housed under standardized con-
itions in a room on a 12 h light/dark cycle with food and water
vailable ad libitum.  All experimental protocols described in this
tudy were approved by the regulations stipulated by Guangdong
edical College Animal Care Committee which follows the proto-
ol outlined in the Guide for the Care and Use of Laboratory Animals
ublished by the US National Institute of Health (NIH publication
o. 85-23, revised 1985).
.2. Surgical operation
Peripheral nerve injury was produced by SNL according to a
reviously described method [11]. Brieﬂy, under chloral hydrate
nesthesia (300 mg/kg, intraperitoneally, Sigma–Aldrich), a skin
ncision (3–4 cm)  was made in the midline lumbar region (L4–S1).
he L6 transverse process was identiﬁed, freed of muscular attach-
ents, and partially removed with the help of bone ronguers. This
xposed the L5 spinal nerve. The L5 was then carefully isolated and
ightly ligated distal to the dorsal root ganglion (DRG) with 6–0 silk
hread. The surgical procedures for the sham group were identical
o that of the SNL group, except that the spinal nerves were not
igated.
.3. Intrathecal implantation
Polyethylene (PE) – 10 tube (BD, USA) was implanted into the
ubarachnoid space of the lumbar enlargement for intrathecal drug
dministration. The catheter placement was veriﬁed by observing
ransient hindpaw paralysis induced by intrathecal injection of 2%
idocaine (10 L). Only those rats showing complete paralysis of
oth hind limbs and the tail after the administration of lidocaine
ere used for the subsequent experiments. At the end of each
xperiment, the position of the PE tubing in the intrathecal space
t the lumbar enlargement was visually veriﬁed by exposing the
umbar spinal cord.
.4. Drug administration
Fucoidan (Sigma, St. Louis, MO)  was dissolved in 5% dimethyl-
ulfoxide (DMSO) and then diluted with 0.9% (w/v) saline solution.
nimals were divided into 5 groups for administration: sham-
peration with vehicle (sham group); SNL rats received treatment
ith fucoidan (15 mg/kg, 50 mg/kg, 100 mg/kg) or vehicle (5%
MSO) once daily during the period of days 11–20 inclusively (n = 6
ats per treatment group).ters 571 (2014) 66–71 67
2.5. Mechanical withdrawal threshold (MWT) and thermal
withdrawal latency (TWL)
Behavioral tests were carried out between 8 and 12 am on 1 day
before operation and days 10, 20, 22, 24, 26, 28, 30 after operation,
respectively. Mechanical allodynia was assessed using von Frey ﬁl-
aments (Stoelting, Kiel, WI,  USA) by experimenters blind to group
assignment. The stiffness of the von Frey ﬁlaments was  2, 4, 6, 8, 10,
15, and 20 g. A positive paw withdrawal response was  recorded if
the animal briskly lifted the hindpaw. The mechanical withdrawal
threshold (MWT)  was  determined by the up-down method [2]. To
assess thermal sensitivity, paw-withdrawal latencies to a radiant
heat stimulus were measured using the paw-ﬂick test apparatus
(IITC Life Science, Woodland Hills, CA). The thermal withdrawal
latency (TWL) was recorded as the threshold of thermal sensitivity.
Each hindpaw was  tested ﬁve times at 5 min intervals.
2.6. Tissue harvest
After ﬁnishing the behavioral tests on day 30 post operation,
rats were deeply anesthetized with chloral hydrate (300 mg/kg,
intraperitoneally) and then perfused intracardially with 250 ml
cold saline. The ipsilateral L4–5 spinal cord tissue rostral to the
injury site was removed, dissected on cold ice and removed quickly
to liquid nitrogen for subsequent assays.
2.7. Real-time quantitative polymerase chain reactions
Glial ﬁbrillary acidic protein (GFAP) and macrophage antigen
complex-1 (mac-1) were markers for astrocytic and microglial acti-
vation respectively. Rats were deeply anesthetised with chloral
hydrate (300 mg/kg) and sacriﬁced. Total RNA from the L5 spinal
segments was  extracted with Trizol (GIBCO/BRL Life Technologies
Inc., Grand Island, NY, USA). Complementary DNA  (cDNA) was
synthesized with oligo (dT) 12–18 using Superscript III Reverse
Transcriptase for RT-PCR (Invitrogen, Carlsbad, CA, USA). The
sense primer for GFAP was 5′-GCTGGAGCAAGACAAACATTC-3′, and
the antisense primer was  5′-CCCTACCCACTCCTACATCGT-3′. The
sense primer for mac-1 was 5′-TGGCTGCTACTACCGTCCCT-3′, and
the antisense primer was 5′-CAGGTTGGAGCCGAATAGGT-3′. The
sense primer for GAPDH was 5′-CCCCCAATGTATCCGTTGTG-3′, and
the antisense primer was  5′-TAGCCCAGGATGCCCTTTAGT-3′. Equal
amounts of RNA (1 g) were used to prepare cDNA using the SYBR
Premix Ex Taq TM (Takara, Tokyo, Japan) and analyzed with a real-
time PCR detection system (Applied Biosystems, Foster City, CA,
USA). All values were normalized to GAPDH expression.
2.8. Enzyme-linked immunosorbent assay
Spinal production of TNF-, IL-1 and IL-6 was quantiﬁed by
enzyme-linked immunosorbent assay (ELISA) kits for rats accord-
ing to the manufacturers’ instructions (Biosource USA for IL-1 and
IL-6; R&D Systems for TNF-). Values were expressed as picogram
per milligram protein.
2.9. Western blot analysis
To examine changes in p-ERK expression following SNL, all col-
lected tissue samples were homogenized in an SDS sample buffer
containing a mixture of proteinase and phosphatase inhibitors
(Sigma). The protein concentrations were estimated using the
bicinchoninic acid (BCA) method. Protein samples were separated
on SDS-PAGE gel and transferred to a nitrocellulose membrane.
The membranes were blocked in 10% skimmed milk for 1 h at
room temperature and incubated with the following primary anti-
bodies overnight at 4 ◦C: rabbit anti-pERK (1:1000; Cell Signaling)
6 ce Letters 571 (2014) 66–71
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Fig. 1. The effects of intrathecal fucoidan on SNL-induced mechanical allodynia and
thermal hyperalgesia. SNL injury resulted in prominent mechanical allodynia (A) and
thermal hyperalgesia (B) on day 10 after surgery. The intrathecal administration of
fucoidan (15, 50 or 100 mg/kg, once per day from POD 11–20) signiﬁcantly blocked
SNL-induced mechanical allodynia and thermal hyperalgesia in a dose-dependent8 C. Hu et al. / Neuroscien
nd mouse anti--actin (1:3000, Sigma). The blots were further
ncubated for 1 h at RT with HRP-conjugated secondary antibody
anti-rabbit 1:3000, anti-mouse 1:5000; Amersham Biosciences),
nd washed three times in TBS for 30 min. The immune complexes
ere detected by the enhanced chemiluminescence (ECL) detection
ethod (Amersham) and exposure to ﬁlm. A square of the same
ize was drawn around each band to measure the density and the
ackground near that band was subtracted. Target protein levels
ere normalized against -actin levels and expressed as relative
old changes compared to the sham group.
.10. Statistical analysis
Values are expressed as means ± SEM. For behavioral data, com-
arisons were performed using repeated measures of analysis of
ariance (ANOVA). For others, comparisons were performed using
NOVA followed by Bonferroni tests. Data were analyzed using
PSS 13.0 (Chicago, IL, USA). P < 0.05 was considered signiﬁcant.
. Results
.1. Intrathecal administration of fucoidan attenuates SNL
nduced mechanical allodynia and thermal hypersensitivity in a
ose-dependent manner
To investigate whether fucoidan would reverse established neu-
opathic pain, different doses (15, 50 and 100 mg/kg) of fucoidan
ere injected intrathecally once daily from postoperative day
POD) 11–20, and behavioral experiments were carried out. As
hown in Fig. 1, the sham group did not display signiﬁcant behav-
oral changes. Prominent mechanical and thermal hyperalgesic
ehaviors were established on day 10 after surgery as shown in
he SNL-Veh group. Compared to the SNL-Veh group, treatment
f fucoidan dose-dependently alleviated and reversed mechanical
llodynia and thermal hyperalgesia. Especially, signiﬁcant anal-
esic effect was observed when fucoidan was at doses of 50 and
00 mg/kg.
.2. The effects of fucoidan on SNL-induced spinal glial activation
The analgesic effect of fucoidan might be associated with its
nhibitory effect on microglia and astrocytes. To verify this hypoth-
sis, we studied the expression of glial activation markers in lumbar
pinal cord GFAP (Fig. 2A) and mac-1 (Fig. 2B) expression. Results
howed that on day 30 after SNL, GFAP and mac-1 expression
evels were markedly enhanced in SNL rats compared to the sham-
perated rats (P < 0.01). Administration of various doses of fucoidan
ecreased spinal glial activation markers in a dose-dependent man-
er compared to the SNL-Veh group. Fucoidan, especially in the
ose of 50 and 100 mg/kg, seems to exert higher suppressive effects.
urthermore, fucoidan suppression of spinal glial activation was
ccompanied by its attenuation of behavioral hyperalgesia.
.3. The effects of fucoidan on inﬂammatory cytokines
The inhibitory effect of fucoidan on glia could lead to subsequent
ecreased production of inﬂammatory cytokines. Inﬂammatory
ytokine (TNF-,  IL-1, and IL-6) expression was  analyzed by
LISA (Fig. 3). Results indicated that SNL surgery induced remark-
ble increases of inﬂammatory mediators including TNF-, IL-1
nd IL-6 in the spinal dorsal horn on day 30 after surgery. How-
ver, intrathecal fucoidan signiﬁcantly suppressed the elevations
f these inﬂammatory mediators in a dose-dependent manner.
dditionally, there was a signiﬁcant downregulation of proin-
ammatory cytokines in the dose of 50 and 100 mg/kg fucoidan
reatment group. Moreover, fucoidan inhibition of inﬂammatorymanner. SNL: spinal nerve ligation; POD: postoperative day. n = 6 in each group,
*P  < 0.05, compared to the SNL + Veh group.
cytokines expression was in line with its alleviation of hypersensi-
tivity.
3.4. SNL-induced phosphorylation of ERK in the spinal dorsal
horn is signiﬁcantly inhibited by fucoidan
Substantial evidence implicated that activation of mitogen-
activated protein kinase (MAPK) initiates many signaling cascades
and increases the synthesis of proinﬂammatory mediators follow-
ing peripheral and central nervous injuries [7,17]. To examine
whether MAPK activation was  involved in the suppressive effect
of fucoidan on SNL-induced inﬂammatory cytokines elevation, we
assessed the levels of phosphorylation of ERK using western blot
analysis. Our data showed that on day 30 after SNL, the phosphory-
lation level of ERK was  signiﬁcantly increased in SNL-vehicle group
compared to sham-vehicle group (Fig. 4). Similar to the effect of
fucoidan on inﬂammatory cytokines expression, the SNL-induced
elevation of the phosphorylation level of ERK was  also attenuated
by intrathecal fucoidan.
C. Hu et al. / Neuroscience Letters 571 (2014) 66–71 69
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 < 0.05, P < 0.01 compared to the SNL + Veh group.
. Discussion
In the present study, we observed that repeated admin-
stration of fucoidan dose-dependently attenuates the exist-
ng mechanical allodynia and thermal hyperalgesia induced
y SNL. Subsequently, we investigated the mechanisms that
nderlie the analgesic effect of fucoidan. We  found that
ntrathecal fucoidan could block the maintenance of neuro-
athic pain. Furthermore, fucoidan signiﬁcantly inhibits spinal
strocytic and microglial activation, proinﬂammatory media-
ors production and MAPK activation. Our results suggest that
ig. 3. The effects of intrathecal fucoidan on the proinﬂammatory associated cytokines. 
C)  were determined in the spinal dorsal horn in rats that received different treatments u
hese  inﬂammatory mediators. n = 6 in each group, *, **: P < 0.05, P < 0.01 compared to the 
evels  of proinﬂammatory cytokines are expressed as relative fold changes compared to tinal cord of rats on day 30 after the operation. SNL increased GFAP (A) and mac-1
 6 in each group, *, **: P < 0.05, P < 0.01 compared to the sham + Veh group. #, ##:
fucoidan may  have therapeutic potential in attenuating neu-
ropathic pain, possibly through inhibiting spinal neuroimmune
activation.
Activation of MAPK has been implicated in a number of signal-
ing events that are important for the initiation and maintenance of
neuropathic pain. In the SNL neuropathic pain model, it has been
reported that MAPK including ERK, p-38 and JNK are activated in
microglia and or astrocyte [8,10,22,23]. We also observed ERK acti-
vation in the current study. After repeated intrathecal fucoidan, the
phosphorylation level of ERK declined. A previous study has shown
that partial sciatic nerve ligation (PSNL) increased p38-MAPK
The protein levels of the proinﬂammatory cytokines TNF- (A), IL-1 (B), and IL-6
sing ELISA. Fucoidan signiﬁcantly prevents and reverses SNL-induced increases of
sham + Veh group. #, ##: P < 0.05, P < 0.01 compared to the SNL + vehicle group. The
he Sham + Veh group.
70 C. Hu et al. / Neuroscience Letters 571 (2014) 66–71
Fig. 4. The effects of intrathecal fucoidan on SNL-Induced ERK activation. The expression of phosphorylated (p) ERK (A and B) was revealed by Western blot analysis. On
day  30 after SNL, the phosphorylation level of ERK is signiﬁcantly increased in SNL vehicle rats. After treatment with fucoidan (100 mg/kg) from SNL day 11 to day 20, the
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[hosphorylation level is remarkably decreased. n = 6 in each group, *P < 0.05 comp
xpressed as relative fold changes compared to the Sham + Veh group.
ctivation [13]. However, clonidine suppressed activation of p38
ARK in sensory neurons after nerve injury [4]. As inhibition of
he MAPK signaling pathway could contribute to inﬂammation
esponse, the suppression of MAPK activation by fucoidan fur-
her added to its role on neuropathic pain and the associated
euroimmune activation.
Neuroimmune activation including glial activation and inﬂam-
atory cytokine release contributes to neuropathic pain. After
eripheral and central nervous injuries, astrocytes and microglia
re activated. Then these glial cells release inﬂammatory cytokines,
hich amplify neuronal excitation and pain signaling. Therefore,
rugs that suppress glial activation and inﬂammatory cytokines
roduction may  prevent and reverse neuropathic pain. In this
tudy, we observed that fucoidan suppressed spinal glial activation
nd proinﬂammatory cytokines production. The inhibitory effects
f fucoidan on neuroinﬂammation are in agreement with several
ther studies on the effects of fucoidan on inﬂammation diseases. It
as been shown that fucoidan signiﬁcantly inhibited lipopolysac-
haride (LPS)-activated microglial inﬂammatory responses [18].
oreover, it inhibited the expression of some cytokine/chemokine
n LPS accelerated cerebral ischemic injury rats [9]. In addition,
ucoidan could ameliorate the learning and memory abilities in
-induced Alzheimer’s disease rats [5]. Fucoidan could also atten-
ate ischemia-reperfusion (I/R)-induced myocardial damage and
revent the loss of dopaminergic neurons in a LPS-induced ani-
al  model of Parkinson’s disease [3,12]. These data suggest that
ucoidan has anti-inﬂammatory activities and neuroprotective
ffects. It could be considered for use as a potential treatment for
nﬂammatory and neurodegenerative disorders.
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